Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for ...
Medscape

Teduglutide for Short Bowel Given Positive Response in EU

June 27, 2012 — A novel peptide analogue, teduglutide (Revestive, Nycomed/Takeda), is the first medical treatment recommended for approval by the European Medicines Agency (EMA) for use in adults with ...
Medscape

The Medical and Surgical Management of Short Bowel Syndrome

In the absence of registry data, it is impossible to know the precise incidence and prevalence of short bowel syndrome in the United States. On the basis of European data, the incidence of total ...
Nature

Short Bowel Syndrome and Parenteral Nutrition

Short Bowel Syndrome (SBS) is a multifaceted condition arising from extensive surgical resection of the small intestine, which leads to impaired nutrient absorption and a heightened risk of ...
equities

Zealand Pharma Enrolls First Patient in Phase 3 Trial for Short Bowel Syndrome

Short bowel syndrome is a complex group of diseases caused by the loss (or loss of function) of part of the small and/or large intestine. Patients with short bowel syndrome can’t absorb sufficient ...
Healio

Teduglutide improves stool outcomes in children with short bowel syndrome over 96 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Stool frequency and consistency improved over 96 weeks ...
Business Insider

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially ...

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that the first short bowel syndrome with intestinal failure (SBS-IF) ...
USA Today

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

This new IP supports crofelemer’s global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer ...
Becker's Hospital Review

Short Bowel Syndrome Drug Receives FDA Drug Advisory Committee Recommendation

Gattex (teduglutide), a drug for the treatment of adult short bowel syndrome, has received a recommendation for approval from the FDA’s Gastrointestinal Drugs Advisory Committee, according to a news ...
Healio

STARS: Apraglutide reduces need for parenteral support in short bowel syndrome by week 24

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Apraglutide reduced weekly dependency on parenteral ...
EurekAlert!

Reprogramming gut cells to treat short bowel syndrome

SATB2 deficiency confers small intestinal (ileal) properties on colon cells. Green fluorescent marker bound to cholesterol (top row) and glucose (bottom row) shows absorption of nutrients in: a) Ileal ...